Today's Daily Dose brings you news about ImmunoGen's stock offering; Ascendis securing Orphan Drug Designation for TransCon PTH; Streamline Health's strong quarterly results; FDA granting Rare Pediatric Disease Designation for Cellectar's CLR 131, and Proteostasis' phase I study results of PTI-801 in cystic fibrosis patients.